191 related articles for article (PubMed ID: 9506326)
1. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure.
Nakamura M; Arakawa N; Yoshida H; Makita S; Niinuma H; Hiramori K
Am Heart J; 1998 Mar; 135(3):414-20. PubMed ID: 9506326
[TBL] [Abstract][Full Text] [Related]
2. Vasodilatory effects of C-type natriuretic peptide on forearm resistance vessels are distinct from those of atrial natriuretic peptide in chronic heart failure.
Nakamura M; Arakawa N; Yoshida H; Makita S; Hiramori K
Circulation; 1994 Sep; 90(3):1210-4. PubMed ID: 8087930
[TBL] [Abstract][Full Text] [Related]
3. Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels.
Minami H; Yasu T; Tagawa T; Yamakawa K; Ueda S
Eur J Clin Pharmacol; 2008 Sep; 64(9):859-62. PubMed ID: 18622600
[TBL] [Abstract][Full Text] [Related]
4. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure.
Schmitt M; Gunaruwan P; Payne N; Taylor J; Lee L; Broadley AJ; Nightingale AK; Cockcroft JR; Struthers AD; Tyberg JV; Frenneaux MP
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):911-7. PubMed ID: 15001459
[TBL] [Abstract][Full Text] [Related]
5. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide.
van der Zander K; Houben AJ; Kroon AA; de Leeuw PW
Cardiovasc Res; 1999 Dec; 44(3):595-600. PubMed ID: 10690292
[TBL] [Abstract][Full Text] [Related]
6. [Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3', 5'-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure].
Kobusiak-Prokopowicz M; Swidnicka-Szuszkowska B; Mysiak A
Pol Arch Med Wewn; 2001 Jun; 105(6):475-82. PubMed ID: 11865578
[TBL] [Abstract][Full Text] [Related]
7. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
Chen HH; Cataliotti A; Schirger JA; Martin FL; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1093-7. PubMed ID: 15627648
[TBL] [Abstract][Full Text] [Related]
8. Vasodilating actions of calcitonin gene-related peptide in normal man: comparison with atrial natriuretic peptide.
Ando K; Ito Y; Ogata E; Fujita T
Am Heart J; 1992 Jan; 123(1):111-6. PubMed ID: 1530893
[TBL] [Abstract][Full Text] [Related]
9. Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart failure.
Ishibashi Y; Shimada T; Sakane T; Takahashi N; Sugamori T; Ohhata S; Inoue S; Katoh H; Sano K; Murakami Y; Hashimoto M
J Am Coll Cardiol; 2000 Nov; 36(5):1605-11. PubMed ID: 11079665
[TBL] [Abstract][Full Text] [Related]
10. Abnormal rhythmic oscillations of atrial natriuretic peptide and brain natriuretic peptide in heart failure.
Bentzen H; Pedersen RS; Pedersen HB; Nyvad O; Pedersen EB
Clin Sci (Lond); 2003 Mar; 104(3):303-12. PubMed ID: 12605591
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease.
Osajima A; Okazaki M; Kato H; Anai H; Tsuda Y; Segawa K; Tanaka H; Tamura M; Takasugi M; Nakashima Y
Am J Nephrol; 2001; 21(2):112-9. PubMed ID: 11359018
[TBL] [Abstract][Full Text] [Related]
12. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure.
Nakamura M; Yoshida H; Makita S; Arakawa N; Niinuma H; Hiramori K
Circulation; 1997 Mar; 95(5):1214-21. PubMed ID: 9054852
[TBL] [Abstract][Full Text] [Related]
13. Vascular effects of natriuretic peptides in healthy men.
Komarek M; Bernheim A; Schindler R; Steden R; Kiowski W; Brunner-La Rocca HP
J Cardiovasc Pharmacol Ther; 2004 Dec; 9(4):263-70. PubMed ID: 15678245
[TBL] [Abstract][Full Text] [Related]
14. Natriuretic peptide analogues with distinct vasodilatory or renal activity: integrated effects in health and experimental heart failure.
Rademaker MT; Scott NJA; Koh CY; Kini RM; Richards AM
Cardiovasc Res; 2021 Jan; 117(2):508-519. PubMed ID: 32167565
[TBL] [Abstract][Full Text] [Related]
15. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.
Brunner-La Rocca HP; Kaye DM; Woods RL; Hastings J; Esler MD
J Am Coll Cardiol; 2001 Apr; 37(5):1221-7. PubMed ID: 11300426
[TBL] [Abstract][Full Text] [Related]
16. Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure.
Bentzen H; Pedersen RS; Nyvad O; Pedersen EB
Int J Cardiol; 2004 Feb; 93(2-3):121-30. PubMed ID: 14975537
[TBL] [Abstract][Full Text] [Related]
17. Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man.
Fujita T; Ito Y; Noda H; Sato Y; Ando K; Kangawa K; Matsuo H
J Clin Invest; 1987 Sep; 80(3):832-40. PubMed ID: 3040808
[TBL] [Abstract][Full Text] [Related]
18. Cyclic GMP production by ANP, BNP, and NO during worsening and improvement of chronic heart failure.
Takahashi M; Takeda S; Kurokawa S; Kubo T; Fukuda N; Izumi T
Jpn Heart J; 2003 Sep; 44(5):713-24. PubMed ID: 14587653
[TBL] [Abstract][Full Text] [Related]
19. Attenuated forearm vasodilative response to intra-arterial atrial natriuretic peptide in patients with heart failure.
Hirooka Y; Takeshita A; Imaizumi T; Suzuki S; Yoshida M; Ando S; Nakamura M
Circulation; 1990 Jul; 82(1):147-53. PubMed ID: 2163779
[TBL] [Abstract][Full Text] [Related]
20. Natriuretic peptides in the treatment of heart failure.
Yasue H; Yoshimura M
J Card Fail; 1996 Dec; 2(4 Suppl):S277-85. PubMed ID: 8951590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
